Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders Growth (1y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Teva Pharmaceutical Industries 38.77 Bn 35.04 Bn 1.97 Bn 71.83%
2 Zoetis 34.11 Bn 32.16 Bn 1.62 Bn -0.17%
3 United Therapeutics 23.68 Bn 21.53 Bn 648.10 Mn -14.68%
4 Aurora Cannabis 16.48 Bn 16.40 Bn 33.43 Mn -90.23%
5 Neurocrine Biosciences 16.19 Bn 14.88 Bn 800.70 Mn 2,405.06%
6 Elanco Animal Health 11.44 Bn 11.01 Bn 785.00 Mn -14.93%
7 Alkermes 7.28 Bn 6.77 Bn -116.06 Mn -
8 Lantheus Holdings 6.48 Bn 5.98 Bn 230.92 Mn 62.34%
9 Hims & Hers Health 6.35 Bn 5.60 Bn 396.79 Mn -286.15%
10 Kiniksa Pharmaceuticals International 3.79 Bn 3.32 Bn 193.47 Mn 164.57%

Historic Data

Download Data
DateValue
Mar 31, 2026 164.57%
Dec 31, 2025 1,269.60%
Sep 30, 2025 245.24%
Jun 30, 2025 556.29%
Mar 31, 2025 148.23%
Dec 31, 2024 98.54%
Sep 30, 2024 8.39%
Jun 30, 2024 -126.10%
Mar 31, 2024 -44.29%
Dec 31, 2023 8.39%
Sep 30, 2023 -106.18%
Jun 30, 2023 174.93%
Mar 31, 2023 51.33%
Dec 31, 2022 -105.62%
Sep 30, 2022 833.67%
Jun 30, 2022 51.93%
Mar 31, 2022 49.05%
Dec 31, 2021 -139.12%
Sep 30, 2021 30.32%
Jun 30, 2021 -10.93%